Elucidating High Oral Fluid Exposure Mechanisms of Buprenorphine to Reduce Dental Caries

阐明丁丙诺啡的高口腔液暴露机制以减少龋齿

• 批准号: 10765181
• 负责人: MING HU
• 金额: $ 143.41万
• 依托单位: UNIVERSITY OF HOUSTON
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-21 至 2025-09-20
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10765181
• 关键词: Affect; Animal Model; Attention; Behavior Therapy; Biodistribution; Buprenorphine; Chronic; Cimetidine; Counseling; Data; Dental caries; Dentists; Dosage Forms; Dose; Drug Exposure; Drug toxicity; Drug usage; Effectiveness; Emergency Situation; Environment; Excretory function; Exposure to; FDA approved; Film; Formulation; Future; Gland; Goals; Grant; Health; Hour; Human; Image; Implant; Injections; Knockout Mice; Liquid substance; Mass Spectrum Analysis; Mediating; Medical; Methadone; Minor; Monitor; Mus; Naltrexone; Natural Products; Opioid; Oral; Oral cavity; Oral health; Organ; Organic Cation Transporter; Pathway interactions; Patients; Persons; Pharmaceutical Preparations; Pharmacotherapy; Plasma; Population; Quality of life; Reporting; Research; Rodent; Rodent Model; Role; Saliva; Salivary Glands; Scientist; Spatial Distribution; Stimulant; Streptococcus mutans; Sublingual drug administration; Substance Use Disorder; Tablets; Time; Tissues; Tooth structure; Virulence; analog; design; drug discovery; drug disposition; drug repurposing; efficacy study; experience; in vivo; in vivo Model; inhibitor; medication-assisted treatment; mouse model; opioid use disorder; oral tissue; pathogen; pharmacologic; quorum sensing; side effect; subcutaneous; success

SUMMARY Opioid use disorders (OUD) are having devastating and tragic effects in the USA. There are only three drugs available as a part of medication assisted treatment (MAT), and the newest drug is buprenorphine. Buprenorphine is mostly given as sublingual tablets and films. It is estimated that more than 1 million oral buprenorphine prescriptions were filled in 2018. Multiple reports suggest that buprenorphine is present in high concentrations in the oral fluids after oral (sublingual) buprenorphine administration, typically 10-100 folds higher than its plasma concentrations. The high oral fluid exposure to opioid analogs is well known and used to monitor the presence of opioids in people. Recently, a less known side effects of chronic oral buprenorphine use raised alarm. In January of 2022, FDA issued a warning stating that use of oral buprenorphine formulations (i.e., sublingual tablets and films) may cause serious harm to the teeth in significant percentages of patients who are taking these buprenorphine formulations. This is serious problem for OUD patients because the effective pharmacotherapy options for this population are limited. Without understanding the mechanism of this severe side effects that impact users' health and quality of life, it is difficult to develop effective pharmacological countermeasures. The mechanisms responsible for observed tooth damaging effects are unknown, but we suspected that it is caused by high concentrations of buprenorphine in the oral fluids. We hypothesize that mechanisms responsible for high oral fluid exposure to buprenorphine can be elucidated and oral fluid exposure to buprenorphine exposure can be significantly reduced by saliva stimulant without reducing their systemic exposure. Moreover, the reduced oral fluid drug exposure will lead to fewer dental caries in rodent models of caries. We also hypothesize that high accumulation of buprenorphine in salivary glands elevates oral fluid exposure to buprenorphine and inhibition of their accumulation in the salivary glands will reduce their oral fluid exposure. A mouse model of dental caries that are responsive to varying concentrations of buprenorphine will be established and use to evaluate the impact of high oral fluid exposure to buprenorphine on dental caries in mice. The study team has a rich experience in studying drug glucuronidation (buprenorphine is extensively glucuronidated), and transporter-mediated drug disposition, and is equipped with the proper dosage form (e.g., oral film) and expertise (LC-MS for bioanalysis and mass spectrometry) to understand how oral fluid exposure to buprenorphine could be reduced. Our efficacy study will be led by a dentist-scientist with expertise in studying the virulence of Streptococcus mutans, a primary cariogen. Our study aims to develop “pharmacologic approaches” using the current animal models to support drug discovery and/or repurposing for OUD pharmacotherapeutics with minimal or minor negative impact on dental health. In other words, our research may lead to future selection of drugs to reduce oral cavity concentrations of buprenorphine without negatively impacting the drug's systemic exposure and its intended use for medication assisted treatment in OUD.

概括 阿片类药物使用障碍 (OUD) 在美国造成了毁灭性和悲剧性的影响。只有三种药物。 作为药物辅助治疗 (MAT) 的一部分，最新的药物是丁丙诺啡。 丁丙诺啡主要以舌下片剂和膜剂形式给药，估计超过 100 万口服。 丁丙诺啡处方已于 2018 年配药。多项报告表明，丁丙诺啡存在于高浓度人群中。 口服（舌下）丁丙诺啡后口腔液中的浓度通常高出 10-100 倍 口服高液体暴露于阿片类药物类似物的浓度是众所周知的，并用于监测。 最近，人们发现了长期口服丁丙诺啡的一个鲜为人知的副作用。 2022 年 1 月，FDA 发出警告，指出使用口服丁丙诺啡制剂（即： 舌下含片和薄膜）可能会对相当大比例的患者的牙齿造成严重伤害 服用这些丁丙诺啡制剂对于 OUD 患者来说这是一个严重的问题，因为其效果不佳。 如果不了解这种严重的机制，针对该人群的药物治疗选择是有限的。 副作用影响使用者的健康和生活质量，很难开发有效的药理学 导致观察到的牙齿损伤效应的机制尚不清楚，但我们 怀疑这是由口腔液中高浓度的丁丙诺啡引起的。 可以阐明导致口腔液中丁丙诺啡高暴露的机制，并且口腔液暴露 唾液兴奋剂可以显着减少丁丙诺啡的暴露，而不会降低其全身性 此外，减少口腔液体药物暴露将导致啮齿动物模型中龋齿的减少。 我们还发现唾液腺中丁丙诺啡的大量积累会导致口腔液浓度升高。 接触丁丙诺啡并抑制其在唾液腺中的积累会减少他们的口腔液 对不同浓度的丁丙诺啡有反应的小鼠龋齿模型将发生变化。 建立并用于评估口腔液中大量暴露于丁丙诺啡对龋齿的影响 研究团队在药物葡萄糖醛酸化研究方面有丰富的经验（主要是丁丙诺啡）。 葡萄糖醛酸化）和转运介导的药物处置，并配备适当的剂型（例如， 口腔胶片）和专业知识（用于生物分析和质谱分析的 LC-MS），以了解口腔液暴露的情况 我们的疗效研究将由具有研究专业知识的牙医科学家领导。 我们的研究旨在开发“药理学”。 方法”使用当前的动物模型来支持 OUD 的药物发现和/或重新利用 换句话说，我们的研究可能对牙齿健康产生最小或轻微的负面影响。 导致未来选择药物来降低口腔丁丙诺啡浓度而不产生负面影响 影响药物的全身暴露及其在 OUD 药物辅助治疗中的预期用途。